For six decades, hormone-sensitive lipase , HSL , was textbook material. Discovered in the 1960s, it was described as the enzyme that chops up fat stored inside adipocytes, releasing fatty acids into the bloodstream when the body needs energy. That story was clean, simple, and wrong enough to matter.
New research published in Cell Metabolism in October 2025 reveals that HSL is not just a cytosolic enzyme floating around fat cells burning triglycerides. It also lives in the nucleus of those cells, where it plays a completely different role , one that has nothing to do with fat breakdown and everything to do with keeping the cell itself alive and functional [1]. This is not a minor correction. It is a fundamental rethink of how metabolic disease develops, and it explains something that never fit the old model: why people who lose their fat storage cells develop the same health problems as people who have far too many of them.
The Paradox Nobody Could Explain
The conventional view held that HSL deficiency would cause obesity. If the enzyme responsible for breaking down fat stops working, fat should accumulate. That is what the textbooks predicted.
The textbooks were wrong. Humans born with mutations in LIPE , the gene that codes for HSL , do not become obese. Instead, they lose fat. Their bodies cannot maintain functional adipose tissue. The condition is called lipodystrophy, and it comes with a cascade of problems that look eerily similar to obesity: insulin resistance, type 2 diabetes, fatty liver, high triglycerides [3][5].
In the Old Order Amish cohort studied by researchers, a frameshift deletion in LIPE exon 9 produced exactly this pattern. Carriers had dyslipidemia, hepatic steatosis, systemic insulin resistance, and diabetes , all hallmarks of metabolic disease , despite having reduced, not increased, fat mass [5]. The same counterintuitive finding appeared in mice engineered to lack adipocyte HSL. Knockout mice fed a high-fat diet progressively lost adipose tissue and developed fatty liver, exactly the opposite of what was expected [4].
This is the enzyme paradox. Losing a fat-burning enzyme produces a phenotype that resembles having too much fat. The reason, it turns out, is that HSL does two jobs, not one , and the second job is the one that matters most for tissue health.
What HSL Actually Does in the Nucleus
The Dufau et al. paper in Cell Metabolism traces HSL's behaviour inside adipocytes with precision. During high-fat feeding, HSL accumulates in the cell nucleus. During fasting, it leaves. This is not passive traffic , HSL is shuttled in and out through a specific interaction with SMAD3, a protein that mediates TGF-beta signalling [1]. When HSL is phosphorylated, it gets exported back to the cytosol.
What is HSL doing once inside the nucleus? The evidence suggests it regulates gene expression directly, independent of its enzymatic activity. HSL exerts opposing effects on mitochondrial oxidative phosphorylation and on components of the extracellular matrix [1]. Both of those functions are essential for adipose tissue to remain healthy and expandable.
The 2020 comprehensive review in Progress in Lipid Research had already hinted at this broader role. HSL was known to have wide substrate specificity compared to other neutral lipases, and clinical studies showed dysregulation in conditions ranging from obesity to cancer cachexia [2]. But the nuclear localization finding, published definitively in 2025, changes the conceptual framework. HSL is not merely a lipolytic enzyme. It is a dual-function protein that operates in two cellular compartments doing two entirely different jobs.
When Fat Cells Vanish: The Human Cost of Broken HSL
The clinical picture of LIPE-related lipodystrophy is stark. Patients typically present in adulthood with progressive loss of fat in the lower limbs, sometimes accompanied by unusual upper-body or abdominal fat masses that mimic lipomatosis. Diabetes and insulin resistance appear early. Hypertriglyceridemia can be severe. Liver steatosis , fat deposited in the liver , is common. High blood pressure and neuromuscular problems, including difficulties with gait and balance, round out the syndrome [3].
Eye investigations in these patients revealed something unexpected: numerous auto-fluorescent drusen-like retinal deposits, similar to those seen in age-related macular degeneration [3]. This adds a previously unrecognised ophthalmological dimension to the disease.
Stem cell models derived from LIPE-mutated patients showed the mechanism at cellular level. Adipose stem cells from affected individuals failed to differentiate properly into mature adipocytes. They showed decreased response to insulin, defective lipolysis, and mitochondrial dysfunction [3]. The cells could not form the tissue they were supposed to form.
What is striking is that the same pathway disruption appears in opposite clinical contexts. HSL is dysregulated in obesity, in type 2 diabetes, in lipodystrophy, and in cancer-associated cachexia [2]. That breadth suggests HSL sits at a central regulatory node in adipose tissue biology , and that disrupting it in either direction causes disease.
The New Therapeutic Horizon
Understanding HSL as a nuclear regulator rather than purely a fat-burning enzyme opens treatment possibilities that did not exist before.
The old pharmaceutical target was straightforward: block HSL to reduce fat breakdown and lower circulating fatty acids. That strategy failed in clinical trials because blocking HSL also disrupted whatever the enzyme was doing in the nucleus. You cannot remove one function without removing the other if you do not know they are separate.
The new framing suggests a more nuanced approach. Drugs that specifically target HSL's enzymatic activity while leaving its nuclear functions intact , or, conversely, drugs that enhance nuclear HSL localisation without increasing lipolysis , could decouple the two roles [1][2]. That is a harder drug discovery problem, but it is the right one.
There is also the question of why both obesity and lipodystrophy converge on the same downstream diseases. The likely answer is that adipose tissue must be present and functional to store excess nutrients safely. When fat cells are absent , as in lipodystrophy , nutrients get deposited in the liver, muscle, and pancreas instead, causing the same metabolic mayhem as having too many fat cells that are overloaded and inflamed. HSL, in its nuclear role, appears to be essential for maintaining that functional adipose tissue [1].
What This Means for Metabolic Disease Research
The sixty-year story of HSL is a reminder that biology rarely works the way first described. Enzymes get reclassified. Localisation signals get discovered. Functions that seemed settled get complexity added.
The immediate implication is that the field needs to revisit the distinction between obesity as a disease of excess and lipodystrophy as a disease of deficiency. Both involve disrupted HSL signalling. Both result in adipose tissue dysfunction. Both lead to the same cluster of cardiometabolic complications through different starting points.
For patients, this shift matters practically. Lipodystrophy patients have historically been underdiagnosed and undertreated partly because the condition was framed as rare and exotic. If the underlying biology connects obesity and lipodystrophy through shared pathways, the therapeutic insights from one condition become directly relevant to the other.
The 2025 Cell Metabolism paper sets the agenda for the next phase of research. The key questions are now clear: What genes does nuclear HSL regulate? What proteins interact with it in the nucleus? Can we separate the two functions pharmacologically? And can we identify patients whose metabolic disease is driven by disrupted nuclear HSL rather than simple caloric excess?
We do not yet have those answers. But we have stopped believing the wrong story , which is usually where real progress begins.